Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To assess the absorption, distribution, metabolism and excretion of a single dose of 14C labelled AZD1722 in order to define the rates and routes of elimination of AZD1722 and if formed, metabolites.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| AZD1722 | Experimental | Single oral dose 15 mg of [14C]AZD1722 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AZD1722 | Drug | Single oral dose 15 mg of [14C]AZD1722 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of radioactive dose recovered in urine and feces | Day 1: Pre-dose and up to 168 hours post-dose | |
| Total percentage of radioactive dose recovered from both urine and feces | Day 1: Pre-dose and up to 168 hours post-dose | |
| Concentration of total radioactivity in blood and plasma samples | Timeframe: Day 1: Predose and up to 120 hours | |
| Concentration of AZD1722 in plasma samples | Timeframe: Day 1: Predose and up to 120 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Safety variables (adverse events, vital signs, ECGs, clinical laboratory tests) | up to 50 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | London | United Kingdom |
Not provided
| Label | URL |
|---|---|
| CSR Synopsis | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| C000599417 | tenapanor |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided